Kubagawa H, Kubagawa Y, Jones D, Nasti TH, Walter MR, Honjo K. The Old but New IgM Fc Receptor (FcµR). Curr Top Microbiol Immunol. 2014. 382:3-28. [QxMD MEDLINE Link].
Weaver DJ Jr, Reis ES, Pandey MK, Köhl G, Harris N, Gerard C, et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol. 2010 Mar. 40(3):710-21. [QxMD MEDLINE Link].
Ghannam A, Fauquert JL, Thomas C, Kemper C, Drouet C. Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol Immunol. 2014 Mar. 58(1):98-107. [QxMD MEDLINE Link].
Fairweather D, Frisancho-Kiss S, Njoku DB, Nyland JF, Kaya Z, Yusung SA, et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol. 2006 Mar 15. 176(6):3516-24. [QxMD MEDLINE Link].
Jacobson AC, Weis JJ, Weis JH. Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner. J Immunol. 2008 Apr 1. 180(7):5057-66. [QxMD MEDLINE Link].
Boos L, Campbell IL, Ames R, Wetsel RA, Barnum SR. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol. 2004 Oct 1. 173(7):4708-14. [QxMD MEDLINE Link].
Crider A, Feng T, Pandya CD, Davis T, Nair A, Ahmed AO, et al. Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior. Brain Behav Immun. 2018 May. 70:246-256. [QxMD MEDLINE Link].
Nikiforovich GV, Baranski TJ. Structural mechanisms of constitutive activation in the C5a receptors with mutations in the extracellular loops: molecular modeling study. Proteins. 2012 Jan. 80(1):71-80. [QxMD MEDLINE Link]. [Full Text].
Yu S, Wang D, Huang L, Zhang Y, Luo R, Adah D, et al. The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages. J Biol Chem. 2019 Apr 10. [QxMD MEDLINE Link].
Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A, Md Akhir FN, et al. The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. J Immunol. 2016 Jun 1. 196 (11):4783-92. [QxMD MEDLINE Link].
Tone Y, Wada T, Shibata F, Toma T, Hashida Y, Kasahara Y, et al. Somatic revertant mosaicism in a patient with leukocyte adhesion deficiency type 1. Blood. 2007 Feb 1. 109(3):1182-4. [QxMD MEDLINE Link].
Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009 Mar. 15(3):306-12. [QxMD MEDLINE Link].
Yashoda-Devi BK, Rakesh N, Devaraju D, Santana N. Leukocyte adhesion deficiency type I--a focus on oral disease in a young child. Med Oral Patol Oral Cir Bucal. 2011 Mar 1. 16(2):e153-7. [QxMD MEDLINE Link].
Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. 1980 Jul 1. 152(1):20-30. [QxMD MEDLINE Link].
Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. 2013 Jan. 53(1-2):99-110. [QxMD MEDLINE Link]. [Full Text].
Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol. 2013 Dec 15. 56(3):213-21. [QxMD MEDLINE Link].
Sommerfeld O, Medyukhina A, Neugebauer S, Ghait M, Ulferts S, Lupp A, et al. Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis. Mol Ther. 2021 Jan 6. 29 (1):338-346. [QxMD MEDLINE Link].
Nord KM, Pappert AS, Grossman ME. Pyoderma Gangrenosum-like Lesions in Leukocyte Adhesion Deficiency I Treated with Intravenous Immunoglobulin. Pediatr Dermatol. 2011 Mar. 28(2):156-61. [QxMD MEDLINE Link].
Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, et al. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol. 2000 Nov 15. 165(10):5401-5. [QxMD MEDLINE Link].
Kallenberg CG. Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol. 2015 Oct 12. [QxMD MEDLINE Link].
Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. JMIR Res Protoc. 2020 Apr 7. 9 (4):e16664. [QxMD MEDLINE Link].
Qasim W, Cavazzana-Calvo M, Davies EG, Davis J, Duval M, Eames G, et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics. 2009 Mar. 123(3):836-40. [QxMD MEDLINE Link].
Moutsopoulos NM, Zerbe CS, Wild T, Dutzan N, Brenchley L, DiPasquale G, et al. Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2017 Mar 23. 376 (12):1141-1146. [QxMD MEDLINE Link].